FN2 Earnings Intelligence
Bio-Techne Corporation financials
Bio-Techne Corporation (TECH) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 est. | 6/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $199.1 | $172.6 | $180.6 | $151.8 | $162.2 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $931 | $1,105.6 | $1,136.7 | $1,159.1 | $1,219.6 | $1,207.2 | $1,261.7 |
| % Growth | 26.0% | 18.7% | 2.8% | 2.0% | 5.2% | -1.0% | 4.5% |
| Gross Profit | $632.8 | $756.5 | $769.8 | $769.7 | $790.3 | - | - |
| % Margin | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | - | - |
| EBITDA | $325 | $397.7 | $406.2 | $318.4 | $212.2 | - | - |
| % Margin | 34.9% | 36.0% | 35.7% | 27.5% | 17.4% | - | - |
| Net Income | $140.4 | $272.1 | $285.3 | $168.1 | $73.4 | - | - |
| % Margin | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | - | - |
| Diluted EPS | $3.47 | $6.63 | $1.76 | $1.05 | $0.46 | $1.92 | $2.05 |
| % Growth | -40.4% | 91.1% | -73.5% | -40.3% | -56.2% | 318.1% | 6.8% |
| Operating Cash Flow | $352.2 | $325.3 | $254.4 | $299 | $287.6 | - | - |
| CapEx | $44.3 | $44.9 | $38.2 | $62.9 | $31 | - | - |
| Free Cash Flow | $307.9 | $280.4 | $216.1 | $236.1 | $256.6 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 | 6/30/2026 est. | 6/30/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $931 | $1,105.6 | $1,136.7 | $1,159.1 | $1,219.6 | $1,207.2 | $1,261.7 |
| Gross Profit | $632.8 | $756.5 | $769.8 | $769.7 | $790.3 | - | - |
| EBITDA | $325 | $397.7 | $406.2 | $318.4 | $212.2 | - | - |
| Net Income | $140.4 | $272.1 | $285.3 | $168.1 | $73.4 | - | - |
| Diluted EPS | $3.47 | $6.63 | $1.76 | $1.05 | $0.46 | $1.92 | $2.05 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $199.1 | $172.6 | $180.6 | $151.8 | $162.2 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $341 | $256 | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $352.2 | $325.3 | $254.4 | $299 | $287.6 |
| Capital Expenditure | $44.3 | $44.9 | $38.2 | $62.9 | $31 |
| Free Cash Flow | $307.9 | $280.4 | $216.1 | $236.1 | $256.6 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 6/30/2021 | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 26.0% | 18.7% | 2.8% | 2.0% | 5.2% |
| Gross Margin | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% |
| EBITDA Margin | 34.9% | 36.0% | 35.7% | 27.5% | 17.4% |
| Net Margin | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% |
| FCF Margin | 33.1% | 25.4% | 19.0% | 20.4% | 21.0% |
| Diluted EPS Growth | -40.4% | 91.1% | -73.5% | -40.3% | -56.2% |